RxDoctor Payments Data

Thirupath Reddy, MD

Internal Medicine · San Jose, CANPI 1992808992

Payments from drug & device makers

$36,285in general payments, 2019–2025

Across 245 payments — averaging $148.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$18K
  • Biotronik Inc.$14K
  • Abbott$2K
  • AstraZeneca$343
  • Novartis$273
  • E.r. Squibb & Sons, L.L.C.$233
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$10,80030%
  • Speaking & faculty fees$2,1006%
  • Travel & lodging$16,04244%
  • Food & beverage$7,26320%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,285 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$290,123
Medicare patients
1,189
Services billed
3,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$290,139
XareltoRivaroxaban60$73,286
EntrestoSacubitril/Valsartan56$63,881
BrilintaTicagrelor28$29,593
FarxigaDapagliflozin Propanediol11$6,301
Rosuvastatin Calcium30$1,608
Metoprolol Tartrate169$1,336
Amiodarone Hcl21$1,252
Atorvastatin Calcium97$976
Albuterol Sulfate HfaAlbuterol Sulfate24$946
Metoprolol Succinate47$829
ClopidogrelClopidogrel Bisulfate51$810
Nifedipine ErNifedipine12$694
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$651
Carvedilol62$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$290,139255 claims
Johnson & JohnsonXarelto$187$73,28660 claims
NovartisEntresto$273$63,88156 claims
AstraZenecaBrilinta, Farxiga$343$35,89339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →